CSL Behring has paid out $91 million upfront for biotech Calimmune and gains a preclinical asset for sickle cell disease and β-thalassemia.
Novartis is paying $31 million upfront for gevokizumab, a price that reflects the battering its prospects took as a development program unraveled.
Kite Pharma and its hotly anticipated CAR-T med are the chosen ones after Gilead's year-plus search for a worthy buyout target.
The takeover will see Regenxbio pay about $86 million to add two of early-stage gene therapies to its pipeline.
Shares in Paratek were up almost a third in premarket trading this morning after Bloomberg said the company, gearing up to file a new antibiotic, is…
Encore Dermatology has picked up a late-stage pipeline drug via a deal with India's Dr. Reddy's Laboratories.
The multiyear agreement positions Lilly to work with Topas on drugs that convey tolerance to antigens linked to inflammation or autoimmune diseases.
Former Zealand Pharma chief David Horn Solomon, M.D., has taken up the challenge of guiding biotech Akari during an increasingly tumultuous period.
The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.
The deal continues the retreat from infectious diseases Medivir began after Gilead and others cornered the hepatitis C market.